TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15360994

Group type: EXPERIMENTAL
Intervention: Audit plus Strategic feedback (n=17)
Number of subjects: 30345

Group type: COMPARATOR
Intervention: Audit only feedback (n=16)
Number of subjects: 30345

Group type: COMPARATOR
Intervention: Control group (n=19)
Number of subjects: 30345
Study: 11425157

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus azithromycin (Regimen A) for 12 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Cotrimoxazole plus doxycycline (Regimen B) for 20 weeks
Number of subjects: 65
Study: 9342586

Group type: EXPERIMENTAL
Intervention: Nicotine inhalation at 30 degrees C
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nicotine inhalation at 40 degrees C
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nicotine inhalation at 20 degrees C
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: In vitro results at 30 degrees C
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: In vitro results at 40 degrees C
Number of subjects: 18
Study: 8376688

Group type: EXPERIMENTAL
Intervention: Enalapril (2.5 to 20 mg/day)
Number of subjects: 4228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4228
Study: 3757162

Group type: EXPERIMENTAL
Intervention: 16 mg dexamethasone i.v.
Number of subjects: 26

Group type: COMPARATOR
Intervention: N-saline i.v. with cytotoxics
Number of subjects: 26
Study: 30326480

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 1034

Group type: COMPARATOR
Intervention: Obesity, hypertension, and baseline blood pressure
Number of subjects: 1034
Study: 26671818

Group type: EXPERIMENTAL
Intervention: Carfilzomib with dexamethasone
Number of subjects: 929

Group type: COMPARATOR
Intervention: Bortezomib with dexamethasone
Number of subjects: 929
Study: 24921948

Group type: EXPERIMENTAL
Intervention: Multicomponent environmental school-based intervention with 11 components
Number of subjects: 1348

Group type: COMPARATOR
Intervention: Control group (7 schools)
Number of subjects: 1348
Study: 23009324

Group type: EXPERIMENTAL
Intervention: RKT‐7700
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: CT‐80
Number of subjects: 49

Group type: COMPARATOR
Intervention: GAT
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Corneal Thickness
Number of subjects: 49
Study: 20363993

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no atorvastatin therapy)
Number of subjects: 54
Study: 19005437

Group type: EXPERIMENTAL
Intervention: Dark chocolate (700 mg of flavonoids/day for one week)
Number of subjects: 28
Study: 16161727

Group type: EXPERIMENTAL
Intervention: Psychotherapy (8 sessions of cognitive behavioral therapy) plus antidepressant pharmacotherapy over 3 months
Number of subjects: 109

Group type: COMPARATOR
Intervention: Assessment‐only condition
Number of subjects: 109
Study: 12564947

Group type: EXPERIMENTAL
Intervention: Quad cane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Standard cane
Number of subjects: 30

Group type: COMPARATOR
Intervention: No cane
Number of subjects: 30
Study: 11123120

Group type: EXPERIMENTAL
Intervention: NTG patch (n = 6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo patch (n = 6)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: NTG patch (n = 5, at H4)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: NTG patch (n = 5, at H23)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: NTG patch (n = 5)
Number of subjects: 12
Study: 9743404

Group type: EXPERIMENTAL
Intervention: N2O (50%)
Number of subjects: 13
Study: 7841703

Group type: EXPERIMENTAL
Intervention: Buserelin intranasal spray (group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Triptorelin depot im every 28 days (group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Untreated (group C)
Number of subjects: 40
Study: 3234301

Group type: EXPERIMENTAL
Intervention: Al-Mg-silicate preparation (MegalacR) administered 45 min after the meal
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (15 subjects)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Patients with PI without antacid
Number of subjects: 13
Study: 31783722

Group type: EXPERIMENTAL
Intervention: Presence of social workers (SW) and community health workers (CHW) in primary care practices
Number of subjects: 341
Study: 31288740

Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia
Number of subjects: 46

Group type: COMPARATOR
Intervention: Isoflurane anaesthesia
Number of subjects: 46
Study: 28077858

Group type: COMPARATOR
Intervention: Usual Control (UC)
Number of subjects: 2550

Group type: COMPARATOR
Intervention: Tight Control (TC)
Number of subjects: 2550

Group type: EXPERIMENTAL
Intervention: Usual Control (UC) and Tight Control (TC) combined
Number of subjects: 2550
Study: 25924691

Group type: EXPERIMENTAL
Intervention: 30 mg oral morphine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 23608758

Group type: EXPERIMENTAL
Intervention: Transportal (TP) technique
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Outside-in (OI) technique
Number of subjects: 76
Study: 22065184

Group type: EXPERIMENTAL
Intervention: Neuromuscular warm-up
Number of subjects: 1492
Study: 19405039

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 90

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 90
Study: 17118827

Group type: EXPERIMENTAL
Intervention: Hyperoxia (ventilated with >96% oxygen before cardiopulmonary bypass)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (standard care without hyperoxia)
Number of subjects: 22
Study: 15504996

Group type: EXPERIMENTAL
Intervention: Inhaled insulin (Exubera) plus bedtime Ultralente
Number of subjects: 335

Group type: COMPARATOR
Intervention: Conventional insulin regimen (two to three injections of regular and NPH insulin)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Inhaled insulin (Exubera)
Number of subjects: 335
Study: 11139801

Group type: EXPERIMENTAL
Intervention: Oral glycoprotein IIb/IIIa antagonists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous glycoprotein IIb/IIIa antagonists
Number of subjects: 0
Study: 9226607

Group type: EXPERIMENTAL
Intervention: Chronic fatigue syndrome patients without psychiatric disorder
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Chronic fatigue syndrome patients with psychiatric disorder
Number of subjects: 69

Group type: COMPARATOR
Intervention: Psychiatric outpatients with chronic depressive disorders
Number of subjects: 69

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 69
Study: 8620374

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide bleaching gel (2 hours exposure)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide bleaching gel (7 hours exposure)
Number of subjects: 0
Study: 30417697

Group type: EXPERIMENTAL
Intervention: Standard 6-week postoperative rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expedited one-session postoperative rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No postoperative rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expedited therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 0
Study: 30399122

Group type: EXPERIMENTAL
Intervention: Naloxone 8 mg
Number of subjects: 199

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 199

Group type: COMPARATOR
Intervention: Naloxone and Saline placebo (combined)
Number of subjects: 199
Study: 26864140

Group type: EXPERIMENTAL
Intervention: Anodal tDCS plus CGT
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham tDCS plus CGT
Number of subjects: 22
Study: 25591446

Group type: EXPERIMENTAL
Intervention: Lessons on healthy food and changes to school vending machines (introduction of lower-calorie foods, food labelling, price reductions)
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Lessons on healthy food and changes to school vending machines
Number of subjects: 614

Group type: COMPARATOR
Intervention: Control group ('care as usual')
Number of subjects: 614
Study: 23334070

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg ponezumab
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg ponezumab
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1 mg/kg ponezumab
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 3 mg/kg ponezumab
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 10 mg/kg ponezumab
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 22334928

Group type: EXPERIMENTAL
Intervention: sinuforte (1.3 mg per procedure, once daily for 7 days)
Number of subjects: 30
Study: 18668648

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 70

Group type: COMPARATOR
Intervention: TIVA with propofol-remifentanil
Number of subjects: 70
Study: 16449100

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 12642739

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily for 1 week, azithromycin 500 mg/d for 3 days, amoxicillin 1 g twice daily for 1 week (OAzAm group, n = 80)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Omeprazole 20 mg twice daily for 1 week, azithromycin 500 mg/d for 3 days, tinidazole 500 mg twice daily for 3 days (OAzT group, n = 80)
Number of subjects: 160
Study: 10699899

Group type: EXPERIMENTAL
Intervention: Pamidronate (90 mg intravenous infusion every 3-4 weeks)
Number of subjects: 751
Study: 9524466

Group type: EXPERIMENTAL
Intervention: Amine fluoride (AmF) solution containing 1% fluoride, biannual applications for 5 years
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo solution, biannual applications for 5 years
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Amine fluoride (AmF) solution containing 1% fluoride
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 284
Study: 8105512

Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg i.v. bolus)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Atropine (7 micrograms/kg i.m.)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline (control for famotidine)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Famotidine (without hG infusion)
Number of subjects: 14
Study: 3513684

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 181

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, and fluorouracil)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Hormone withdrawal after tamoxifen
Number of subjects: 181
Study: 31747012

Group type: EXPERIMENTAL
Intervention: Oxidized regenerated cellulose (ORC)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Non-oxidized regenerated cellulose (non-ORC)
Number of subjects: 108
Study: 28691598

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (30 min twice a week)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Reference group (lectures in health promotion)
Number of subjects: 116
Study: 27247226

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg intravenously every 2 weeks
Number of subjects: 60
Study: 24051659

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg · d(‐1), n = 8 subjects)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (n = 4 subjects)
Number of subjects: 12
Study: 23328294

Group type: EXPERIMENTAL
Intervention: sorafenib plus local chemotherapeutic perfusion of cisplatin 40 mg weekly for 2 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: sorafenib alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: sorafenib plus local chemotherapy
Number of subjects: 30
Study: 19849696

Group type: EXPERIMENTAL
Intervention: 0.06% retinyl retinoate applied twice daily for 12 weeks
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 0.06% retinyl retinoate applied twice daily for 8 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo applied for 12 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: 0.075% retinol applied for 8 weeks
Number of subjects: 46
Study: 17855671

Group type: EXPERIMENTAL
Intervention: Idraparinux (2.5 mg once-weekly for 6 months)
Number of subjects: 1215

Group type: COMPARATOR
Intervention: Placebo (for 6 months)
Number of subjects: 1215

Group type: EXPERIMENTAL
Intervention: Idraparinux (6 additional months)
Number of subjects: 1215

Group type: COMPARATOR
Intervention: Vitamin K antagonist (initial treatment)
Number of subjects: 1215
Study: 15559355

Group type: EXPERIMENTAL
Intervention: Microwave endometrial ablation (MEA)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Rollerball electroablation (REA)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Microwave endometrial ablation (MEA) in patients with myomas
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Microwave endometrial ablation (MEA) in patients with BMI ≥ 30 kg/m2
Number of subjects: 322

Group type: COMPARATOR
Intervention: Rollerball electroablation (REA) in patients with BMI ≥ 30 kg/m2
Number of subjects: 322
Study: 11422966

Group type: EXPERIMENTAL
Intervention: Umbilical artery Doppler velocimetry in well-defined studies
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (not using Doppler velocimetry)
Number of subjects: 13
Study: 9040281

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 12
Study: 8201149

Group type: EXPERIMENTAL
Intervention: In-home geriatric assessments with follow-up visits by trained volunteers
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: In-home geriatric assessments
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control group (telephone interviews)
Number of subjects: 254
Study: 3653082

Group type: EXPERIMENTAL
Intervention: Pancuronium 6-8 micrograms kg-1
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30939096

Group type: EXPERIMENTAL
Intervention: Paclitaxel (80 mg/m2) with trastuzumab for 12 weeks, followed by trastuzumab for 9 months
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: PAM50 analysis
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Genotyping
Number of subjects: 410
Study: 30422235

Group type: EXPERIMENTAL
Intervention: Lanreotide (120 mg subcutaneously once every 4 weeks) in addition to standard care (n=153)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Standard care only (target blood pressure <140/90 mm Hg; n=152)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Lanreotide
Number of subjects: 309

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 309
Study: 26987626

Group type: EXPERIMENTAL
Intervention: β2‐1 Fructan supplementation (3×5 g/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 30
Study: 24206841

Group type: EXPERIMENTAL
Intervention: Paracetamol administration for fever (≥37·5°C)
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Insulin administration for hyperglycemia (>11 mmol/L)
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Swallow assessment by a speech pathologist
Number of subjects: 718

Group type: COMPARATOR
Intervention: Swallow screening by a nonspeech pathologist
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Reassessment by a speech pathologist after passing a swallow screen
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Confirmation of safe swallowing after reassessment
Number of subjects: 718
Study: 22502814

Group type: EXPERIMENTAL
Intervention: Low Level Helium Neon (He‐Ne) Laser therapy (λ=632.8 nm, P=24 mW, ED=3.5 J/cm(2))
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Low Level Helium Neon (He‐Ne) Laser therapy
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 121
Study: 19071225

Group type: EXPERIMENTAL
Intervention: 30 microg MDI‐TRE
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 45 microg MDI‐TRE
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 60 microg MDI‐TRE
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 39
Study: 17449572

Group type: EXPERIMENTAL
Intervention: SUC (sucrose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: WAT (water)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ISO (isomaltulose)
Number of subjects: 10
Study: 15946379

Group type: EXPERIMENTAL
Intervention: Drain group
Number of subjects: 94

Group type: COMPARATOR
Intervention: Non-drain group
Number of subjects: 94
Study: 11835024

Group type: EXPERIMENTAL
Intervention: Bivalirudin (bolus of 0.1 mg/kg followed by an infusion of 0.25 mg/kg/h)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Unfractionated heparin (bolus of 70 U/kg followed by an infusion of 15 U/kg/h)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 133
Study: 11198951

Group type: EXPERIMENTAL
Intervention: High-dose supplements of nutrients (specific nutrients not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selenium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diets rich in fruits and vegetables
Number of subjects: 0
Study: 8834126

Group type: COMPARATOR
Intervention: Diabetic nephropathy patients
Number of subjects: 56
Study: 2036692

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125% and fentanyl 4 micrograms.ml‐1 (Group I)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Bupivacaine 0.25% (Group II)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Bupivacaine 0.125% (Group III)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125% and fentanyl (Group I)
Number of subjects: 75
Study: 7236478

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Althesin + enflurane
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Thiopentone + halothane
Number of subjects: 131

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 131
Study: 31122894

Group type: EXPERIMENTAL
Intervention: Eosinophil-guided therapy (37.5 mg of oral prednisolone daily for up to 4 days based on eosinophil count)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Control group (37.5 mg of oral prednisolone daily for 4 days)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Eosinophil-guided therapy
Number of subjects: 318

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 318
Study: 26218727

Group type: EXPERIMENTAL
Intervention: VYC‐20L (Juvéderm Voluma XC) injected in zygomaticomalar subregion
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: VYC‐20L (Juvéderm Voluma XC) injected in anteromedial cheek subregion
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: VYC‐20L (Juvéderm Voluma XC) injected in submalar subregion
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: VYC‐20L (Juvéderm Voluma XC) with higher injection volumes
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: VYC‐20L (Juvéderm Voluma XC) with median injection volume of ≈2.0 mL
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: VYC‐20L (Juvéderm Voluma XC)
Number of subjects: 235
Study: 23967286

Group type: EXPERIMENTAL
Intervention: 40 g/d polyphenol soy protein complex (PSPC) for 17 days
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 21844821

Group type: EXPERIMENTAL
Intervention: Valsartan (VAL)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 48
Study: 19625744

Group type: EXPERIMENTAL
Intervention: Insulin (1 mU.kg(‐1).min(‐1)) and dextrose to maintain euglycemia
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Octreotide (150 microg/h)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Insulin, dextrose, and octreotide
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemia with euglycemia
Number of subjects: 35

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 35
Study: 17355547

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy according to classical Chinese Medicine (Heidelberg Model)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Best medical care (control group)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy
Number of subjects: 47
Study: 15128959

Group type: EXPERIMENTAL
Intervention: Individual placement and support services
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Workplace fundamental skills module (supplementing individual placement and support)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional types of vocational rehabilitation
Number of subjects: 0
Study: 11167431

Group type: EXPERIMENTAL
Intervention: Vital capacity breathing with 8% sevoflurane
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tidal breathing with 8% sevoflurane
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tidal breathing with step-up of sevoflurane
Number of subjects: 60
Study: 11229246

Group type: EXPERIMENTAL
Intervention: Amphotericin B deoxycholate (ABD), 1 mg/kg day on days 1‐20, infusion completed in 2 hours.
Number of subjects: 130

Group type: COMPARATOR
Intervention: Escalating dose of ABD (0.05 mg/kg, 0.1 mg/kg, 0.25 mg/kg, 0.5 mg/kg, 1 mg/kg on days 1‐5, then same dosage on alternate days), infusion completed in 6 hours.
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Group B (newer mode)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Group A (classical mode)
Number of subjects: 130
Study: 7566302

Group type: EXPERIMENTAL
Intervention: Activated powdered charcoal (6 g daily p.o.)
Number of subjects: 23
Study: 2231839

Group type: EXPERIMENTAL
Intervention: Maloprim (pyrimethamine and dapsone) administered fortnightly by village health workers (VHWs)
Number of subjects: 1500
Study: 688736

Group type: EXPERIMENTAL
Intervention: 100 mg spironolactone per day (low dose)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 200 mg spironolactone per day (high dose)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 30703667

Group type: EXPERIMENTAL
Intervention: 9-session intervention arm
Number of subjects: 788

Group type: COMPARATOR
Intervention: Measurement-only control arm
Number of subjects: 788
Study: 28493744

Group type: COMPARATOR
Intervention: Menthol cigarette use
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Fast NMR
Number of subjects: 474